BACKGROUND: Some, but not all, observational studies have suggested an increase in the risk of HIV acquisition for women using injectable hormonal contraception (IHC). METHODS: We used country-level data to explore the effects of reducing IHC use on the number of HIV infections, the number of live births and the resulting net consequences on AIDS deaths and maternal mortality for each country. RESULTS: High IHC use coincides with high HIV incidence primarily in southern and eastern Africa. If IHC increases the risk of HIV acquisition, this could generate 27 000-130 000 infections per year globally, 87-88% of which occur in this region. Reducing IHC use could result in fewer HIV infections but also a substantial increase in live births and maternal mortality in countries with high IHC use, high birth rates and high maternal mortality: mainly southern and eastern Africa, South-East Asia, and Central and South America. For most countries, the net impact of reducing IHC use on maternal and AIDS-related deaths is dependent on the magnitude of the assumed IHC-HIV interaction. CONCLUSIONS: If IHC use increases HIV acquisition risk, reducing IHC could reduce new HIV infections; however, this must be balanced against other important consequences, including unintended pregnancy, which impacts maternal and infant mortality. Unless the true effect size approaches a relative risk of 2.19, it is unlikely that reductions in IHC could result in public health benefit, with the possible exception of those countries in southern Africa with the largest HIV epidemics.
BACKGROUND: Some, but not all, observational studies have suggested an increase in the risk of HIV acquisition for women using injectable hormonal contraception (IHC). METHODS: We used country-level data to explore the effects of reducing IHC use on the number of HIV infections, the number of live births and the resulting net consequences on AIDS deaths and maternal mortality for each country. RESULTS: High IHC use coincides with high HIV incidence primarily in southern and eastern Africa. If IHC increases the risk of HIV acquisition, this could generate 27 000-130 000 infections per year globally, 87-88% of which occur in this region. Reducing IHC use could result in fewer HIV infections but also a substantial increase in live births and maternal mortality in countries with high IHC use, high birth rates and high maternal mortality: mainly southern and eastern Africa, South-East Asia, and Central and South America. For most countries, the net impact of reducing IHC use on maternal and AIDS-related deaths is dependent on the magnitude of the assumed IHC-HIV interaction. CONCLUSIONS: If IHC use increases HIV acquisition risk, reducing IHC could reduce new HIV infections; however, this must be balanced against other important consequences, including unintended pregnancy, which impacts maternal and infant mortality. Unless the true effect size approaches a relative risk of 2.19, it is unlikely that reductions in IHC could result in public health benefit, with the possible exception of those countries in southern Africa with the largest HIV epidemics.
Authors: Margaret C Hogan; Kyle J Foreman; Mohsen Naghavi; Stephanie Y Ahn; Mengru Wang; Susanna M Makela; Alan D Lopez; Rafael Lozano; Christopher J L Murray Journal: Lancet Date: 2010-04-09 Impact factor: 79.321
Authors: Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Barbra A Richardson; Tsungai Chipato; Roy Mugerwa; Josaphat Byamugisha; Nancy Padian; David D Celentano; Robert A Salata Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Ronald H Gray; Xianbin Li; Godfrey Kigozi; David Serwadda; Heena Brahmbhatt; Fred Wabwire-Mangen; Fred Nalugoda; Mohamed Kiddugavu; Nelson Sewankambo; Thomas C Quinn; Steven J Reynolds; Maria J Wawer Journal: Lancet Date: 2005-10-01 Impact factor: 79.321
Authors: Mary Mahy; Charlotte Lewden; Martin W G Brinkhof; Francois Dabis; Jean-Michel Tassie; Yves Souteyrand; John Stover Journal: Sex Transm Infect Date: 2010-12 Impact factor: 3.519
Authors: Jeffrey W Eaton; Leigh F Johnson; Joshua A Salomon; Till Bärnighausen; Eran Bendavid; Anna Bershteyn; David E Bloom; Valentina Cambiano; Christophe Fraser; Jan A C Hontelez; Salal Humair; Daniel J Klein; Elisa F Long; Andrew N Phillips; Carel Pretorius; John Stover; Edward A Wenger; Brian G Williams; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Simon Wandel; Matthias Egger; Ram Rangsin; Kenrad E Nelson; Caroline Costello; Charlotte Lewden; Tom Lutalo; Anthony Ndyanabo; Jim Todd; Lieve Van der Paal; Albert Minga; Marcel Zwahlen Journal: Sex Transm Infect Date: 2008-08 Impact factor: 3.519
Authors: Summer Day; Susan M Graham; Linnet N Masese; Barbra A Richardson; James N Kiarie; Walter Jaoko; Kishorchandra Mandaliya; Vrasha Chohan; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2014-08-01 Impact factor: 3.731
Authors: Lisa B Haddad; Chelsea B Polis; Anandi N Sheth; Jennifer Brown; Athena P Kourtis; Caroline King; Rana Chakraborty; Igho Ofotokun Journal: Curr HIV/AIDS Rep Date: 2014-12 Impact factor: 5.071
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Renee Heffron; Nelly Mugo; Edwin Were; James Kiarie; Elizabeth A Bukusi; Andrew Mujugira; Lisa M Frenkel; Deborah Donnell; Allan Ronald; Connie Celum; Jared M Baeten Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Puja Bagri; Ramtin Ghasemi; Joshua J C McGrath; Danya Thayaparan; Emma Yu; Andrew G Brooks; Martin R Stämpfli; Charu Kaushic Journal: J Virol Date: 2020-12-09 Impact factor: 5.103